Goodwin

Dan Karelitz

Deals
9
Latest
Aug 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 9 deals
Deals by year
Dan Karelitz: deals by year0920252026 YTD: 8 M&A2026 YTD: 1 Equity raisings92026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Dan Karelitz was named on, most recent first
Aug 2026 Amylyx Pharmaceuticals ––Follow-on offeringLegal adviser to the issuerAnnounced575.2Biotech+1Amylyx Pharmaceuticals equity raising
Jun 2026 Vendr –Vertice TechnologyAcquisitionLegal adviser to Vendr (target)Announced–SaaS+1Vertice Technology acquisition of Vendr
May 2026 Anagram Therapeutics ––StakeLegal adviser to Anagram Therapeutics (target)Announced–Biotech+2Stake in Anagram Therapeutics
May 2026 Perfuse Therapeutics –BayerAcquisitionLegal adviser to Perfuse Therapeutics (target)Announced300.0Biotech+2Bayer acquisition of Perfuse Therapeutics
Apr 2026 Shionogi-Apnimed Sleep Science ApnimedShionogi & Co.AcquisitionLegal adviser to Apnimed (seller)Announced100.0Pharma+1Shionogi & Co. acquisition of Shionogi-Apnimed Sleep Science
Apr 2026 CathWorks –MedtronicAcquisitionLegal adviser to CathWorks (target)Announced585.0Medtech+1Medtronic acquisition of CathWorks
Apr 2026 Kelonia Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Kelonia Therapeutics (target)Announced7,000.0Biotech+2Eli Lilly and Company acquisition of Kelonia Therapeutics
Apr 2026 Worldwide rights to Kenalog Bristol-Myers SquibbSubsidiary of Piramal PharmaAsset saleLegal adviser to subsidiary of Piramal Pharma (acquirer)Announced35.0PharmaSubsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog
Mar 2026 Pikavation SynnovationNovartisAcquisitionLegal adviser to Synnovation Therapeutics (seller)Announced2,000.0Biotech+2Novartis acquisition of Pikavation

Deals where Dan Karelitz is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.